Boothbay Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boothbay Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-324,400	Closed	-$921K	–	1494
2024 Q1	$921K	Sell	324,400 -72,100	-18%	-$943K	0.02%	783
2023 Q4	$5.84M	Buy	396,500 +254,200	+179%	+$3.9M	0.15%	161
2023 Q3	$2.61M	Buy	+142,300	New	+$3.01M	0.06%	412
2023 Q2	–	Sell	-30,000	Closed	-$880K	–	1779
2023 Q1	$880K	Buy	+30,000	New	+$1.04M	0.02%	1051
2022 Q4	–	Sell	-44,700	Closed	-$1.26M	–	1981
2022 Q3	$1.26M	Buy	44,700 +1,000	+2%	+$24.9K	0.03%	772
2022 Q2	$842K	Buy	43,700 +13,300	+44%	+$158K	0.02%	902
2022 Q1	$391K	Buy	+30,400	New	+$687K	0.01%	1442

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's AMLX Position: Q1 2025 in Review

Boothbay Fund Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 80,543 shares — an estimated $304K sold.

Boothbay Fund Management first reported a position in AMLX in Q1 2022 and held it in 7 quarters. The position peaked at $3.23M in Q4 2023. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

Boothbay Fund Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 80,543 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $304K.
Boothbay Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Boothbay Fund Management's Amylyx Pharmaceuticals position peaked at $3.23M in Q4 2023.
136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.